U.S. company Sundance Diagnostics has licensed genetic markers from Max Planck Innovation that predict suicide risk when antidepressant drugs are prescribed. The new test, based on research carried out at the Max Planck Institute for Psychiatry, should help doctors to decrease the risk of suicidality in patients treated with antidepressants who show certain gene markers.
Image: DNA microarrays are used for diagnostics and to study the expression of genes. A further application is that of genome analysis.
© MPI of Psychiatry
Max Planck Society spin-offs usually emerge either from its biology and medical section or from its chemistry, physics and technology section and address the development of new technologies. A spin-off of MPI for Comparative Public Law and International Law now takes on research in the field of humanities that will eventually assist in peace processes as well as in the reform of the legal systems of developing and transition countries.
Picture: The Max-Planck-Institute for Comparative Public Law and International Law in Heidelberg
The Lead Discovery Center GmbH (LDC), which was established by Max Planck Innovation and the Max Planck Society in 2008 to make better use of the potential offered by outstanding basic research, can report another success: An innovative kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) last year, has reached an important transition milestone. Bayer has successfully advanced this kinase inhibitor program into pre-clinical development with the goal of eventually advancing this candidate into oncology clinical development.
Picture: Research at the LDC
The Life Science Inkubator in Bonn promotes new research team: Scientists from the Life Science Inkubator (LSI), which was established by the technology transfer organisation Max Planck Innovation with the aim of facilitating spin-offs in the field of the life sciences, want to explore new directions in the area of pain therapy. The aim is to suppress pain using weak electric and mechanical stimuli. The stimulation will be generated using special bandages with integrated high-tech chips. Preliminary studies indicate that this process is particularly suited to the alleviation of chronic pain.
Picture: The caesar resarch center in Bonn, residence of the LSI (©caesar)
When exploiting the economic potential of scientific discoveries, the problem often arises that a technology in the form developed at the Max Planck institutes (MPI) is not sufficiently close to the market for industry. With the establishment of the Lead Discovery Center GmbH (LDC) and the Life Science Inkubator GmbH & Co KG (LSI), we have created two very successful companies to bridge this innovation gap.
Picture: The Lead Discovery Center GmbH was jointly developed by Max Planck Innovation and the Max Planck Society as a novel approach to advance findings from excellent basic research into the development of medicines. © LDC
High-tech microscopes are not the only thing needed to obtain crystal clear images from the nanocosmos. Scientists can only make such minute details visible with the help of special fluorescent dyes. Max Planck Innovation, the technology transfer organisation of the Max Planck Society, has signed a licensing agreement with the company Abberior GmbH for the development of such dyes.
Our start-up managers from Max Planck Innovation just got the caesar spin-off KonTEM GmbH under way. The new company, which has been founded in November, is a new spin-off from the caesar research centre and has developed an innovative phase contrast system for transmission electron microscopes (TEM). The new technology enables scientists to achieve better contrast and high object resolution at the same time, opening up new potential for the testing of biological samples.